Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-5573a
- Development stage
- Discontinued
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DS-5573a is an afucosylated humanized monoclonal antibody that targets the immunoregulatory protein B7-homologue 3 (B7-H3, also known as CD276), which is highly expressed in a variety of tumors and associated with poor prognosis. By binding to B7-H3 on tumor cells, DS-5573a blocks B7-H3-mediated signaling and exerts antitumor effects primarily through enhanced antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The drug was developed by Daiichi Sankyo for the treatment of cancers expressing B7-H3. Preclinical studies demonstrated significant antitumor activity in models with functional effector immune cells[1][2][5][6][8].
- Other names
- anti-B7-H3 antibody DS-5573aanti-B-7-H3 antibody DS-5573aanti-B 7-H3 antibody DS-5573aafucosylated humanized anti-B7-H3 monoclonal antibody
02
Targets
B7-H3
Beyond the preview
Go deeper on DS-5573a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-5573a.